Clinical Trial Update: Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial of fludarabine, cytarabine, and pegcrisantaspase for relapsed or refractory leukemias was terminated; the update notes the study's termination at …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Blast Phase Chronic Myeloid Leukemia Bcr-abl1-positive
• Chronic Myeloid Leukemia Bcr-abl1-positive
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Fludarabine (Fludarabine)
• Pegcrisantaspase (Pegcrisantaspase)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Status: TERMINATED